A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Phase 3
600
about 6.4 years
6–17
20 sites in CT, FL, KY +9
About this study
This trial is testing the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine. Participants who previously completed studies for migraine are being offered a chance to continue taking eptinezumab.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Eptinezumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
eptinezumab
Primary: Number of Participants With Treatment Emergent Adverse Events
Secondary: Change From Baseline in Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS) Score at Weeks 12, 24, and 36
Neurology